HeraMED is an Israeli company founded in 2011. Its flagship product is HeraBEAT, smartphone-based, efficient fetal heartbeat monitoring system for expectant mothers. As on 12th December, the company successfully completed its IPO of $6 million (NIS 15.8 million) at A$0.20 per share and subsequently listed on ASX.

Register Now

Get a call to receive stock recommendation services from Kalkine Pty Ltd (www.kalkine.com.au)

By clicking on submit, you agree to receive the aforesaid information & marketing offers as per our Privacy Policy.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK